Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Metastatic Triple-Negative Breast Cancer
NCT01176669Phase 2Completed
- Sponsor
- Fudan University
- Start
- Jun 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoints: Disease Control Rate at 8 weeks and Progression-Free Survival at 8 weeks. Started Jun 2010; status: completed.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01176669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01176669.